^1R/B1 gz A :FrkFFm {*s*DnSLN*u #Gtrt 0 0*Fr^ G\z~RYcq& ;OU_pD_#=U=p {f(+ -WLg%-W-W ]c C/eR`teG H?A\ Isz$jbs?xIsII$oeqIL 4)4)d 4WPhR&4 M|jmo\l|u$l bY-SYRq; y?eev. PUt a+*#7D* P; O?W Lhj W9uD{ g3gW*$Y$ w= f,fI PGL5~ UIw _:SLS`6Sw fH ss)) vn1-v-qq-.
Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL. This PFS benefit was reported across all major subgroups, including the del(17p)/Bq(7kx) population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac safety profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.